UPCC 46420: Phase I Open Label Multicenter Dose Escalation Study of YTB323 in Adult Patients with CLL/SLL and DLBCL
Enrolling By Invitation
18-99 years
All
Phase
1
Brief description of study
Please refer to Section 2 of the full protocol (Objectives and endpoints) Please refer to Section 2 of the full protocol (Objectives and endpoints) Please refer to Section 2 of the full protocol (Objectives and endpoints)
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: Between 18 Years - 99 Years
-
Gender: All
Updated on
01 Aug 2024.
Study ID: 844671
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
